Denmark — Novo Nordisk plans to invest DKK 15.9 billion (approximately EUR 2.1 billion) starting in 2023 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases.